Multiple Myeloma Clinical Trial
Official title:
MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
The primary objective of this study is to analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib in the treatment of multiple myeloma with bad prognosis, in order to evaluate the response and relapse rates
Multiple Myeloma is a plasma cell disorder characterized by an uncontrolled proliferation of
bone marrow plasma cells leading to skeletal destruction with bone pain, anemia, renal
failure, hypercalcemia, recurrent bacterial infections and extramedullary plasmacytomas. It
accounts for 1% of all malignancies and slightly more than 10% of hematologic malignancies,
with an annual incidence of about four per 100.000. Although this disease is incurable with
a median survival of about 3 years, remarkable treatment advances have been recently made,
including high-dose therapy followed by stem cell rescue and, particularly, the introduction
of novel promising agents with new mechanisms of action.
The treatment with alquilant agents, melphalan or cyclophosphamide combined with prednisone
has a median of no more than 3 years survival rate in approximately 50%. The chemotherapy
combination and high-dose dexamethasone increases response rate with minimal effects in
survival benefit. The limited efficacy of conventional treatment produced the introduction
of the high-dose therapy followed by a stem cells transplant in order to increase
antitumoral effect and prolong disease-free overall survival.
This way, autologous stem cells transplant has turned into optimal treatment for patients
younger than 65 years with myeloma. Nevertheless there is increasing evidence that it
benefits only patients who showed complete disease remission after transplantation.
The transcendental factor that determines the CR post-transplantation achievement is the
initial chemotherapy- sensitivity disease, measuring the rapidity and the grade of response
(rapidity of maximum response assessment) and the pre-transplantation M protein level (i.e.,
the grade of response to the initial treatment).
On the other hand, the treatments with alquilant agents can impede the obtention of adequate
numbers of stem cells that make impossible the autotransplantation practice. For this reason
nowadays the treatments based on dexamethasone are used as initial chemotherapy.
However, these regimens and particularly AVD have less activity than alquilant agents
treatment. Bortezomib has shown a fast antimyeloma activity (response after 1 or 2 cycles)
in refractory patients, where myelosuppression and cellular injury are not observed.
Alternating bortezomib and dexamethasone as pre-transplant induction regimen would show the
following advantages:
1. a rapid and high effect raised by means of the use of two drugs with proven activity
when they are administered separately,
2. absence of stem cells injury,
3. different toxicity types avoiding the habitual side effects because of the
dexamethasone abuse, when this one is administered in every cycle as it happens in AVD
type regimens.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |